WO1995002406A2 - Use of benzothiophenes and benzofurans for the treatment of inflammatory bowel disease and inflammation assay method - Google Patents
Use of benzothiophenes and benzofurans for the treatment of inflammatory bowel disease and inflammation assay method Download PDFInfo
- Publication number
- WO1995002406A2 WO1995002406A2 PCT/US1994/007240 US9407240W WO9502406A2 WO 1995002406 A2 WO1995002406 A2 WO 1995002406A2 US 9407240 W US9407240 W US 9407240W WO 9502406 A2 WO9502406 A2 WO 9502406A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- carbons
- inclusive
- inflammation
- treatment
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Definitions
- the present invention provides novel therapeutic uses of certain known benzothiophenes and benzofurans compounds. It has been found that these compounds are useful in the treatment of inflammatory bowel diseases such as Crohn's disease, ileitis, ischemic bowel disease, and ulcerative colitis.
- the present invention also provides the use of an assay which follows a biochemical marker that serves as a noninvasive index of inflammation.
- IBD Inflammatory bowel diseases
- IBD can be broadly categorized into two different diseases, Crohn's disease and ulcerative colitis. Treatment regimens have many similarities even though the diseases have widely different presenting symptoms and their response to treatment varies.
- treatment was limited to sulfasalazine and high-level immunosuppression with corticosteroids. Allergy and intolerance to sulfasalazine and systemic side effects caused by corticosteroids have interfered with effective treatment.
- new agents that have been utilized in IBD improve medical management by achieving a decrease in the medication-induced side effects and by increasing the number of patients entering and being maintained in remission.
- T and B lymphocytes polymorphonuclear leukocytes, mast cells, eosinophils, basophils, tissue macrophages, and monocytes all have a vital role in the cellular inflammatory response.
- the inflammatory response is an essential reaction to environmental stimuli, but, in the process of protection, many toxic compounds such as eosinophilic basic protein and oxygen-derived free radicals invoke damage to the gastrointestinal mucosa. Modifying the inflammatory response may be useful in limiting the tissue damage while not interfering with the beneficial aspect of inflammation.
- TNBS trinitrobenzens sulfonic acid
- the present invention is concerned with the use of certain known benzothiophenes and benzofurans of the formula
- R 1 , R 4 , and R 5 are independently H, alkyl of from 1 to 12 carbons, inclusive, alkoxy of from l to 12 carbons, inclusive, hydroxy, aryl, R 1 taken twice having each on adjacent carbons such that the two R x s together are methylenedioxy, nitro, amino, substituted amino, mercapto, alkylthio of from 1 to 4 carbons inclusive, alkylsulfinyl of from 1 to 4 carbons, inclusive, alkylsulfonyl of from 1 to 4 carbons, inclusive, arylthio, arylsulfinyl, arylsulfonyl, or halogen;
- R 2 is H, alkyl of from 1 to 12 carbons, inclusive, alkoxy of from 1 to 12 carbons, inclusive, arylmethoxy, amino, substituted amino, mercapto, alkylthio of from 1 to 4 carbons, inclusive, alkylsulfinyl of from 1 to 4
- the present invention also provides an assay which follows inflammation in vitro or in vivo, regardless of its etiology.
- the assay follows a biochemical marker that serves as a noninvasive index of inflammation.
- urine is collected from an individual, and the urine is analyzed for the presence of the biochemical marker, 8-hydroxydeoxyguanosine, as an indicator of inflammation.
- Figure 1 shows how trinitrobenzenesulfonic acid (TNBS) exposure increased the average rate of 8-OH-dGUA excretion in a rat model by 276% over controls.
- TNBS trinitrobenzenesulfonic acid
- Figure 2 similar to Figure 1 and a repetition of the first experiment, shows how exposure to trinitrobenzenesulfonic acid (TNBS) increased the average rate of 8-OH-dGUA excretion in a rat model by 349% and 254% over controls.
- TNBS trinitrobenzenesulfonic acid
- 5-Methoxy-3- (1-methyl- ethoxy) -N-lH-tetrazol-5-ylbenzo[b]thiophene- 2-carboxamide monosodium salt reduced this increase to levels statistically indistinguishable from controls.
- Alkyl of from 1 to 4 carbons, inclusive is methyl, ethyl, propyl, butyl, or isomeric forms thereof.
- Alkyl of from l to 12 carbons, inclusive is methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl octyl, nonyl, etc, and includes isomeric forms of the alkyl of from 1 to 6 carbons, inclusive. Alkyl of from 1 to 6 carbons, inclusive, are preferred.
- Alkoxy of from 1 to 12 carbons, inclusive is methoxy, ethoxy, propoxy, butoxy, etc, and includes isomeric forms of alkoxy of from 1 to 6 carbons, inclusive. Alkoxy of from 1 to 6 carbons, inclusive are preferred.
- Substituted amino in mono- or di-alkylamino wherein the alkyl may be the same or different from
- Halogen is chloro, bromo, fluoro, iodo, or trifluoromethyl.
- Aryl is phenyl or substituted phenyl having 1 or
- substitutions such as halogen, alkyl of from 1 to 6 carbons, inclusive, alkoxy of from 1 to 6 carbons, inclusive, hydroxy, nitro, amino, substituted amino, and the like.
- compositions are prepared from compounds of Formula I and salts thereof described as the present invention having inert pharmaceutical carriers.
- Inert, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, dispersible granules, capsules, cachets, and suppositories.
- a solid carrier can be 1 or more substances which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, or tablet disintegrating agents; it can also be an encapsulating material.
- the carrier is a finely divided solid which is in admixture with the finely divided active compound of Formula I.
- the active compound is mixed with carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
- the powders and tablets preferably contain from 5% or 10% to about 70% of the active ingredient.
- Suitable solid carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, a low melting wax, cocoa butter, and the like.
- the term "preparation” is intended to include the formulation of the active compound with encapsulating material as carrier providing a capsule in which the active component (with or without other carriers) is surrounded by carrier, which is thus in association with it.
- cachets are included. Tablets, powders, cachets, transdermal and transmucosal systems, and capsules can be used as solid dosage forms suitable for oral administration.
- Liquid form preparations include solutions, suspensions, and emulsions. As an example, water or water-propylene glycol solutions may be mentioned for parenteral injection. Liquid preparations can also be formulated in solution in aqueous polyethylene glycol solution.
- Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizing, and thickening agents as desired.
- Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, i.e., natural or synthetic gums, resins, methyl cellulose, sodium carboxymethyl cellulose, and other well-known suspending agents.
- the pharmaceutical preparation is in unit dosage form.
- the preparation is subdivided into unit doses containing appropriate quantities of the active component.
- the unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, for example, packeted tablets, capsules, and powders in vials or ampoules.
- the unit dosage form can also be a capsule, cachet, or tablet itself or it can be the appropriate number of any. of these in packaged form.
- the compounds of structural Formula I can be prepared and administered in a wide variety of oral and parenteral dosage forms.
- the compounds of structural Formula I compounds can also be administered intravenously.
- a useful oral dosage is between 1 and 50 mg/kg
- a useful parenteral dosage is between 1 and 50 mg/kg
- a useful intravenous dosage is between 1 and 50 mg/kg.
- the quantity of active compound in a unit dose of preparation may be varied or adjusted from 1 to 100 mg according to the particular application and the potency of the active ingredient.
- the compounds utilized in the pharmaceutical method of this invention are administered at the initial dosage of about 0.1 mg to about 21 mg/kg daily.
- a daily-dose range of about 0.35 mg to about 12 mg/kg is preferred.
- the dosages may be varied depending upon the requirements of the patient, the severity of the condition being treated and the compound being employed. Determination of the proper dosage for a particular situation is within the skill of the art. Generally, the treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day if desired.
- the present invention also provides an assay which follows inflammation in vitro or in vivo, regardless of its etiology.
- the assay follows a biochemical marker that serves as a noninvasive index of inflammation.
- the assay is surprisingly advantageous because of its noninvasive character. Inflammation is usually monitored in animal models by sacrificing the animal and assessing the histopathology at the site of infusion of inflammatory mediators, a process which requires looking at different animals at each time point.
- the present invention employs an HPLC assay to follow a biochemical urinary marker that serves as a noninvasive index of inflammation.
- DNA is susceptible to hydroxylation by free radicals produced during inflammation. If they become hydroxylated, DNA bases are enzymatically excised and subsequently excreted intact into the urine.
- deoxyguanosine is preferentially hydroxylated at the 8' site by hydroxyl radical attack to form 8-hydroxydeoxyguanosine, which subsequently appears intact in the urine where it can be quantified.
- benzothiophene and benzofuran compounds of the present invention moderate inflammatory bowel disease (IBD) is based on examining the urinary excretion of 8-hydroxy- deoxyguanosine (8-OH-dGUA) as an indicator of in vivo hydroxyl radical production.
- the urinary excretion is preferably analyzed by high-pressure liquid chromatographic procedures. Nevertheless, it should be understood that the present invention is not limited as such. Those of ordinary skill in the art will know different analytical tools for detecting a biochemical marker from a sample.
- the urine sample is partially purified using an ion exchange solid phase extraction resin. These resins are known to those of skill in the art.
- the partially purified sample is then run out on high-pressure liquid chromatography, preferably using an electrochemical detector to qualify the biochemical marker peak.
- a rat model of IBD was used in this example where trinitrobenzenesulfonic acid (TNBS) was instilled into the bowel at the start of the experiment to initiate an inflammatory response.
- Ethanol was used to dissolve the TNBS and to breach the mucous barrier.
- TNBS-induced inflammation occurred in a dose-dependent manner, and persisted for at least several weeks before moderating.
- Administration of benzothiophene and benzofuran compounds such as 5-methoxy-3- (1-methylethoxy) -N-lH-tetrazol- 5-ylbenzotb]thiophene-2-carboxamide to the rat model in this example demonstrated substantial improvement to bowel lesions in the rat.
- mice were given under light ether anesthesia an enema of saline in 50% ethanol (controls) or trinitrobenzenesulfonic acid (TNBS; 75 mg/kg) in 50% ethanol.
- Animals thereafter received via oral gavage either saline or 7.5 mg/kg of the test compound, 5-methoxy-3- (1-methylethoxy) -N-lH-tetrazol- 5-ylbenzo[b]thiophene-2-carboxamide, dissolved in saline on a daily basis.
- Urine was collected overnight from animals housed individually in metabolic cages, the volume was measured, and an aliquot frozen.
- TNBS exposure increased the average rate of 8-OH-dGUA excretion by 276% over controls ( Figure 1) .
- the test compound reduced this increase to levels statistically indistinguishable from controls.
- Experiment 2 contained two groups exposed to TNBS and not given the test compound; TNBS exposure increased the average rate of 8-OH-dGUA excretion by 349% and 254% over controls ( Figure 2) .
- Daily oral dosage of the test compound reduced this TNBS-induced increase to levels statistically indistinguishable from controls.
- the average excretion rate presented for each group was the average of 160 observations
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP7504574A JPH09500130A (en) | 1993-07-15 | 1994-07-11 | Benzothiophene and benzofuran as agents for use in the treatment of inflammatory bowel disease and method for assaying inflammation |
EP94923904A EP0789569A2 (en) | 1993-07-15 | 1994-07-11 | Use of benzothiophenes and benzofurans for the treatment of inflammatory bowel disease and inflammation assay method |
AU73961/94A AU7396194A (en) | 1993-07-15 | 1994-07-11 | Use of benzothiophenes and benzofurans for the treatment of inflammatory bowel disease and inflammation assay method |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9204593A | 1993-07-15 | 1993-07-15 | |
US08/092,045 | 1993-07-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1995002406A2 true WO1995002406A2 (en) | 1995-01-26 |
WO1995002406A3 WO1995002406A3 (en) | 1995-04-27 |
Family
ID=22231123
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1994/007240 WO1995002406A2 (en) | 1993-07-15 | 1994-07-11 | Use of benzothiophenes and benzofurans for the treatment of inflammatory bowel disease and inflammation assay method |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0789569A2 (en) |
JP (1) | JPH09500130A (en) |
AU (1) | AU7396194A (en) |
CA (1) | CA2163542A1 (en) |
MX (1) | MX9405380A (en) |
WO (1) | WO1995002406A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6433005B1 (en) | 2000-12-05 | 2002-08-13 | Syntex (U.S.A.) Llc | Benzofuran and benzothiophene derivatives as anti-inflammatory agents |
WO2004058747A1 (en) * | 2002-12-24 | 2004-07-15 | Arthron Limited | Fc receptor modulating compounds and compositions |
WO2004108714A1 (en) * | 2003-06-05 | 2004-12-16 | Warner-Lambert Company Llc | Cycloalkylsulfanyl substituted benzo[b]thiophenes as therapeutic agents |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4863923A (en) * | 1988-07-01 | 1989-09-05 | Eli Lilly And Company | Method of inhibiting superoxide release |
-
1994
- 1994-07-11 CA CA002163542A patent/CA2163542A1/en not_active Abandoned
- 1994-07-11 AU AU73961/94A patent/AU7396194A/en not_active Abandoned
- 1994-07-11 EP EP94923904A patent/EP0789569A2/en not_active Withdrawn
- 1994-07-11 WO PCT/US1994/007240 patent/WO1995002406A2/en not_active Application Discontinuation
- 1994-07-11 JP JP7504574A patent/JPH09500130A/en active Pending
- 1994-07-14 MX MX9405380A patent/MX9405380A/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4863923A (en) * | 1988-07-01 | 1989-09-05 | Eli Lilly And Company | Method of inhibiting superoxide release |
Non-Patent Citations (1)
Title |
---|
GASTROENTEROLOGY, vol.104, no.4, April 1993 page A137 LOW, J.E. ET AL 'GASTRIC CYTOPROTECTIVE EFFECTS OF CI-959 AGAINST THE EROSIVE EFFECT OF ETHANOL, INDOMETHACIN AND ASPIRIN' * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6433005B1 (en) | 2000-12-05 | 2002-08-13 | Syntex (U.S.A.) Llc | Benzofuran and benzothiophene derivatives as anti-inflammatory agents |
WO2004058747A1 (en) * | 2002-12-24 | 2004-07-15 | Arthron Limited | Fc receptor modulating compounds and compositions |
US7332631B2 (en) | 2002-12-24 | 2008-02-19 | Trillium Therapeutics Inc. | Fc receptor modulating compounds and compositions |
US7910770B2 (en) | 2002-12-24 | 2011-03-22 | Trillium Therapeutics Inc. | Fc receptor modulating compounds and compositions |
WO2004108714A1 (en) * | 2003-06-05 | 2004-12-16 | Warner-Lambert Company Llc | Cycloalkylsulfanyl substituted benzo[b]thiophenes as therapeutic agents |
Also Published As
Publication number | Publication date |
---|---|
AU7396194A (en) | 1995-02-13 |
EP0789569A2 (en) | 1997-08-20 |
WO1995002406A3 (en) | 1995-04-27 |
JPH09500130A (en) | 1997-01-07 |
MX9405380A (en) | 1995-01-31 |
CA2163542A1 (en) | 1995-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU713569B2 (en) | Use of a r-nsaid in a protective composition for the treatment of colorectal cancer | |
US11690831B2 (en) | Treatment of autoimmune diseases with combinations of RXR agonists and thyroid hormones | |
Tozaki et al. | Colon-specific delivery of R68070, a new thromboxane synthase inhibitor, using chitosan capsules: therapeutic effects against 2, 4, 6-trinitrobenzene sulfonic acid-induced ulcerative colitis in rats | |
US8026282B2 (en) | Phenoxyalkylcarboxylic acid derivatives in the treatment of irritable bowel syndrome | |
WO2005082349A1 (en) | Composition for the treatment of obesity comprising fumagillol derivative | |
US20180318336A1 (en) | Pentosan polysulfate sodium for the treatment of sickle cell disease | |
JPS62158210A (en) | Rectal absorption form of l-dopa | |
KR101390144B1 (en) | Therapeutic agent for inflammatory bowel disease | |
US20220143074A1 (en) | Chondroitin sulfate polysaccharide, and semi-synthetic preparation method therefor and use thereof | |
US20210069192A1 (en) | Use of neutrophil elastase inhibitors in liver disease | |
WO2000035867A1 (en) | Novel ligands of nuclear receptor | |
CA2003856C (en) | Therapeutic agent for renal disorders | |
EP3373923A1 (en) | Formulation of l-ornithine phenylacetate | |
WO1995002406A2 (en) | Use of benzothiophenes and benzofurans for the treatment of inflammatory bowel disease and inflammation assay method | |
KR20010083123A (en) | Therapeutic agents for allergic diseases | |
CA3028828C (en) | Application of methyl 4-[9-(6-aminopuryl)]-2(s)-hydroxybutyrate in preparation of medicaments for treating psoriasis and vitiligo | |
CN101212980A (en) | Use of macrolides for treating intestinal inflammation | |
CN115671118B (en) | Application of brown alginate oligosaccharides | |
JPH05320047A (en) | Hepatic function improving medicine | |
CN115531373A (en) | Application of butylphthalide or derivatives thereof in preparation of medicine for treating diabetic nephropathy | |
EP0891772A2 (en) | Therapeutic agent for rheumatic disease comprising nonsteroidal anti-inflamatory drug and phenylpropionic acid derivative | |
JPH0662403B2 (en) | Drugs for treating or preventing kidney disease | |
JP2002502409A (en) | Use of anti-inflammatory steroids for the treatment of chronic inflammatory bowel disease | |
JP2000080030A (en) | Agent for preventing and treating granuloma | |
JPH09227372A (en) | Agent for inhibiting adhesion or infiltration of leukocyte and agent for preventing or treating inflammation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU CA JP NZ |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU CA JP NZ |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2163542 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1994923904 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1994923904 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1994923904 Country of ref document: EP |